FDA compliance official highlights priorities, return to onsite inspections, and warning letter trends

Regulatory News

Regulatory NewsJoanne S. Eglovitch

Audit/inspectionCDERComplianceGMPPharmaceuticalsQuality Assurance and ControlQuality management system/QMSRegulatory Intelligence/PolicyUnited States